<DOC>
	<DOCNO>NCT02731040</DOCNO>
	<brief_summary>The purpose study determine whether woman atypical subtrochanteric diaphyseal femoral fracture treatment bisphosphonates osteoporosis , genetic predisposition unusual fracture .</brief_summary>
	<brief_title>Exome Sequencing Atypical Femoral Fractures</brief_title>
	<detailed_description>In 2010 , Task Force convene American Society Bone Mineral Research ( ASBMR ) investigate apparent association atypical subtrochanteric diaphyseal femoral fracture ( AFFs ) long-term bisphosphonate ( BP ) treatment give important common disorder osteoporosis ( OP ) . ( 1,2 ) Because investigator report ( 2 ) 2009 prodromal lesion AFFs OP resemble femoral pseudofractures encounter rare adult form hypophosphatasia ( HPP ) , ( 3-5 ) recommend sequence tissue non-specific alkaline phosphatase ( TNSALP ) gene OP AFF patient determine mutation polymorphisms TNSALP genetically predispose OP AFFs . ( 2 ) In 2012 , investigator report 55-year-old woman treat four year BPs presume OP suffer simultaneous atraumatic bilateral AFFs . ( 4 ) Upon sequence TNSALP , heterozygous mutation change arginine ( Arg ) histidine ( His ) ( c.212 G &gt; A , p.Arg71His ) discover investigator document investigator ' large cohort HPP patient . She undiagnosed HPP although pre-BP serum ALP persistently low ( 26 U/L , Nl 32 - 116 U/L ) . The investigator recruit sequenced TNSALP 24 new OP AFF patient give BPs , identify second OP AFF patient carry TNSALP defect . ( 3 ) These two OP AFF patient TNSALP defect support investigator ' hypothesis ( ) high-impact rare genetic variant TNSALP , perhaps gene , predispose OP AFFs . ( 4 ) Furthermore , investigator report 2009 ( 2 ) prodromal lesion OP AFFs resemble femoral pseudofractures see another , prevalent , heritable metabolic bone disease , X-linked hypophosphatemia ( XLH ) . This common genetic cause osteomalacia , ( 6 ) inherit X-linked dominant trait cause deactivating mutation PHEX gene . Osteoporosis ( OP ) complex disorder likely involve effect multiple low-impact , common change human genome alter bone remodel and/or mineralization . ( 7-9 ) The investigator propose high-impact , rare , genetic variant predispose OP patient AFFs . Treatment BPs could engender OP AFFs . The investigator ' hypothesis : High-impact rare variant ( i.e. , mutation ) occur genes/proteins regulate pyrophosphate/phosphate homeostasis BP metabolism predispose OP AFFs unmask OP patient give BPs . Identification variant guide OP therapy , perhaps individual basis ( i.e. , `` personalize medicine '' ) , ( 9 ) reduce incidence OP AFFs . The investigator identify high-impact rare genetic variant use whole exome sequence two patient group : 1 ) woman use BPs OP one AFF , 2 ) woman use BPs OP AFF . The investigator focus genes/proteins : ) regulate pyrophosphate/phosphate effect , ii ) others regulate BP metabolism , iii ) associate OP . The investigator use gene burden analysis determine whether excess novel rare genetic variant group AFFs .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Femoral Fractures</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Female Previous and/or current use bisphosphonate therapy management osteoporosis For inclusion fracture group must : sustain one atypical subtrochanteric diaphyseal femoral shaft fracture ( ) define 2010 ASBMR task force .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>